SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : CLTR COULTER PHARMACEUTICAL
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: biowa who wrote (447)12/7/1999 10:18:00 AM
From: Vector1  Read Replies (1) of 666
 
Al,
It would be very risky imo to use Zev in combo with CHOP without using dosemitry. Also remember that DNA does not have an interest in Zev.
The complete response rates are out on Zev. for Rit naive patients who are moderately sick ie failed two prior chemo rounds. 21%. This is inferior to Bex which has achieved higher complete responses in sicker patients.

Lets see, Zev is more convienient and may be cheaper. Bex has a slightly better side effect profile and is more likely to result in a complete response. Complete responses have correlated to longer remissions. I do not think this is that tough a call.

V1
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News